Alefacept
- Generic Name
- Alefacept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 222535-22-0
- Unique Ingredient Identifier
- ELK3V90G6C
- Background
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
- Indication
As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
- Associated Conditions
- -
- Associated Therapies
- -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 3
- Registration Number
- NCT01319851
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT01267643
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT01226420
- Locations
- 🇺🇸
Fred Hutch Cancer Research Center, Seattle, Washington, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- John Murray
- Target Recruit Count
- 1
- Registration Number
- NCT00953329
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT00832585
- Locations
- 🇺🇸
Rush University Medical Center - Department of Dermatology, Chicago, Illinois, United States
A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Joshua Zeichner
- Target Recruit Count
- 1
- Registration Number
- NCT00815633
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Safety and Tolerability of Repeat Courses of IM Alefacept
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2008-11-20
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT00794807
- Locations
- 🇩🇪
Psoriasis Study center, The interdisciplinary group of Molecular Immunopathology, Berlin, Germany
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 175
- Registration Number
- NCT00692172
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 78
- Registration Number
- NCT00674063
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 195
- Registration Number
- NCT00673556
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.